Belgium’s nicotine replacement therapy (NRT) sector is developing within a public-health environment increasingly focused on reducing tobacco consumption. The country’s established pharmacy network, changing tobacco regulations and continued demand for structured quitting support shape the use of products such as nicotine patches, gum, lozenges and inhalators. These factors contribute to a relatively mature category in which growth is expected to remain gradual.
The Belgium NRT smoking cessation aids market was valued at USD 33.05 million in 2025 and is projected to reach USD 35.82 million by 2032, registering a compound annual growth rate (CAGR) of 1.16% between 2026 and 2032. The report estimates that the sector will reach USD 33.51 million in 2026. This moderate trajectory reflects an established product category operating within a tightly regulated nicotine environment.
Smoking Patterns Continue to Support Demand for Cessation Assistance
Although smoking prevalence has declined over time, tobacco consumption remains a public-health concern in Belgium. The latest Health Interview Survey findings from Sciensano provide useful context for understanding the population that may consider quitting support. In 2023–2024, 17.6% of people aged 15 and above reported regular smoking, including 12.8% who smoked daily. The proportion of regular smokers has fallen from 19.4% in 2018.
Quitting intentions and previous attempts also indicate continued demand for cessation assistance. According to the same survey, 36% of daily smokers had tried to stop smoking during the preceding 12 months, while 38.8% anticipated attempting to quit in the following year. These findings illustrate the continuing need for accessible support options, although an intention to quit does not necessarily translate into the purchase or use of NRT products.
Sciensano’s findings are available through its Health Interview Survey 2023–2024 results, which provides national information on tobacco use and other health determinants.
Nicotine Patches Retain the Leading Product Position
Product preference in Belgium is strongly influenced by convenience, familiarity and the practical requirements of a quitting routine. NRT patches accounted for approximately 45% of the category share in 2025, making them the leading product type in the country. Their established position is associated with discreet application and once-daily use, which can make them a convenient option for people seeking a structured approach to nicotine replacement.
The broader product range includes NRT gum, inhalators, lozenges and other NRT products. Each format offers a different method of administration, giving consumers and healthcare professionals several options to consider when selecting cessation support. Gum and lozenges provide oral nicotine replacement, while inhalators offer another format for users who prefer an alternative to patches.
The report also identifies gradual diversification beyond conventional product formats. NRT inhalators are expected to record comparatively faster growth, while oral sprays are gaining attention among consumers looking for more flexible approaches to managing cravings. Nevertheless, the established position of patches demonstrates the importance of familiar products in a category where trust and ease of use influence purchasing decisions.
Pharmacy Distribution Shapes Purchasing Behaviour
Belgium’s distribution structure is particularly concentrated around physical retail channels. Retail offline accounted for approximately 95% of sales in 2025, reflecting the importance of pharmacies and other specified offline healthcare-related outlets in the distribution of NRT products.
Pharmacies play an important role because consumers may seek information about product formats, dosage instructions and the suitability of different nicotine replacement options. Pharmacist guidance can be relevant for individuals who are beginning a quit attempt or considering a change from one NRT format to another. This professional interaction also distinguishes the category from everyday consumer products that are commonly purchased through general retail outlets.
The strong offline concentration, however, creates a distinctive commercial environment. With purchasing activity centred on pharmacies, product discovery is more closely connected to consumer intent and healthcare recommendations than to broad retail visibility. Online pharmacies, brand-owned websites and e-commerce marketplaces form part of the report’s segmentation, but their combined contribution remains comparatively limited against the dominant offline channel.
Tobacco Regulation Is Reshaping the Cessation Environment
Belgium has introduced several measures intended to reduce tobacco and nicotine consumption. The prohibition on disposable e-cigarettes took effect on 1 January 2025, while restrictions on the visibility of tobacco products at authorised points of sale began in April 2025. These measures form part of a wider policy direction aimed at limiting tobacco exposure and strengthening public-health protection.
Such regulation provides important context for the NRT category, although it should not be interpreted as a direct or automatic transfer of demand from e-cigarettes to nicotine replacement products. Consumers may respond differently to policy changes, and decisions to use NRT can depend on personal motivation, professional advice, product availability and the perceived suitability of treatment options.
The World Health Organization has highlighted Belgium’s tobacco-control priorities, including the need for sustained action against tobacco-related harm and the regulation of newer nicotine products. Its article, Tobacco control in Belgium: aim high – act now!, provides further context on the country’s policy environment.
Digital Support Creates Scope for More Connected Quit Attempts
Digital tools represent a potential area of development alongside established NRT products. Mobile applications, progress tracking, reminders and behavioural support features can help individuals organise their quitting attempts and maintain engagement with cessation plans. When appropriately designed, these tools may complement professional guidance and product-based support.
For manufacturers and service providers, the opportunity lies in connecting product use with accessible information and ongoing support rather than relying exclusively on conventional product promotion. Digital engagement may be particularly relevant in Belgium, where pharmacy-led distribution and restrictions on nicotine-related promotion influence how consumers discover and evaluate cessation options.
However, digital support should be viewed as a complementary approach rather than a replacement for clinical advice or established cessation services. Its effectiveness depends on the quality of the information, user engagement and the extent to which digital tools are integrated into an individual's broader quitting plan.
Competition Remains Concentrated Among Established Companies
The competitive landscape is relatively concentrated despite the presence of more than five companies active in Belgium’s NRT smoking cessation aids sector. The report estimates that the top three companies collectively account for approximately 90% of the market share, indicating that established brands maintain a strong position.
Kenvue Belgium NV is identified as the leading company, with its Nicorette brand accounting for approximately 54.7% value share in 2025. Its portfolio includes patches, gum, lozenges and sprays, allowing it to serve consumers with different product preferences. Omega Pharma Belgium NV, which distributes Perrigo’s NiQuitin, held the second position with approximately 31.8% share.
Haleon Belgium SA is also identified among the leading companies. The report further notes the acquisition of the Nicotinell brand by Dr. Reddy’s Laboratories, a development that could influence competitive activity as the brand’s commercial presence evolves. The report also covers companies including Johnson & Johnson Consumer NV, Janssen-Cilag NV and GSK Consumer Healthcare.
Outlook: Steady Demand Within a Regulated Healthcare Setting
Belgium’s NRT sector is expected to experience measured growth through 2032. The projected increase from USD 33.05 million in 2025 to USD 35.82 million in 2032 reflects a mature category supported by ongoing smoking cessation needs, established pharmacy distribution and continued public-health action.
NRT patches are likely to remain an important product format, while inhalators and other alternatives contribute to product diversification. The dominance of offline sales and the concentration of leading companies will continue to shape the competitive environment. At the same time, digital support may provide additional ways to connect consumers with structured quitting assistance.
Overall, the sector’s development will depend on the interaction between tobacco-control policies, consumer willingness to quit, pharmacy access and the availability of trusted cessation products. With smoking still affecting a meaningful proportion of Belgium’s adult population, nicotine replacement products are expected to retain a role in the country’s broader tobacco cessation landscape.
Comments (0)
Want to join the discussion?
Log In to Comment